Global cancer supportive care therapeutics market to see negligible growth to $12.4 billion by 2022
According to GBI Research, negligible growth can be attributed to the patent expiries of some of the therapy area’s most…
Sign in
Sign in
Recover your password.
A password will be e-mailed to you.
Browsing Category
Management
Partnerships with healthcare organisations, government aid disaster management
Shripad Desai, MD and Country Director , Americares India Foundation, Mumbai, explains how synergy between NGOs, pharmaceutical…
Head and neck cancer market offers fertile ground for investors as disease understanding improves
According to GBI Research, there are 112 first-in-class programmes in the head and neck cancer pipeline, acting on 87 distinct…
The data integrity triad
Chinmoy Roy, Data Integrity SME, US and Arjun Guha Thakurta, Director, Life Science Consulting, a ConvalGroup Company, India,…
Russia’s pharma market to double to $39 bn by 2021
Implementation of a state programme to improve the healthcare industry has also had a positive impact on domestic production
French pharma market to stagnate as govt embraces generics to cut health expenditure
The market is set to decline from $35.5 bn in 2017 to $34.16 bn in 2021
Indian pharma industry continues to face headwinds: ICRA
Increased regulatory scrutiny and consolidation of supply chain in the US market resulting in pricing pressures along with…
Don’t shut down the pharmacy of the developing world
Shailly Gupta, Deputy Head, MSF Access Campaign (India) emphaises the need to ensure availability of affordable medicines within…
Marsh India’s EH&B Survey 2017: Broaden your employee benefits insurance portfolio
The 9th edition of Marsh India’s Employee Health & Benefits Survey analyses both employer and employee perspectives, to gain a…
Roche to gain most as Biogen remains leader in neurodegenerative drugs market by 2022
According to GBI research Ocrelizumab is expected to become a blockbuster drug within three years of its launch and will be…
Pfizer, Novartis and Eli Lilly set to compete in the HER2-/HR+ breast cancer market
GlobalData forecasts all inhibitors to collectively produce sales of $4.8 billion by 2023 in the US, Spain, UK, Italy, Germany,…
Betting on BEAT
Bouyed up with promising research results, Glenmark seems to be revving up for some major out-licensing deals. Do they finally…
Oncology companion diagnostics market will approach $414 million by 2023: GlobalData
APAC region to see highest growth rate driven by increased evidence and increasing uptake of low-cost molecular tests
Asia-Pacific seasonal influenza vaccines market to surpass $1.7 billion by 2022: GBI Research
Growth will primarily be driven by increasing affordability, rising healthcare access in India and China, and subsidised…
Antibacterial drugs market will hit $35.6 billion by 2022, as efforts increase to tackle…
Use of protein synthesis inhibitors to grow but vaccines will be leading revenue generating drugs
US regulations hit global PMB M&As
Mergermarket in the global Pharma, Medical & Biotech (PMB) sector report for Q1 –Q4 2016, highlights that total deal values…
APAC COPD market set to hit $7.3 bn by 2022
According to GBI Research, the prevalence of COPD is expected to increase significantly across the APAC markets as the smoking…
Raring to grow
Laurus Labs, post a successful IPO, is embarking on the next phase of its growth, armed with the advantage of its core…
A wave of change
Dr Charu Manaktala, Senior Medical Director & Head of Asia Pacific Biosimilars Centre of Excellence, Strategic Drug…
Dyslipidemia market poised for strong growth, surpassing $29.2 bn by 2025
The strong growth will be primarily driven by the launches of three proprotein convertase subtilisin/ kexin type 9 (PCSK9)…